(Q24200446)

English

Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease

scientific article

In more languages

Statements

scholarly article

0 references

0 references

Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease (English)

0 references

chronic obstructive pulmonary disease

0 references

Phillippa Poole

3

object named as

Phillippa Poole

author given names

Phillippa

author last names

Poole

1 reference

PubMed publication ID

19 October 2023

author name string

Luis Javier Nannini

1

author given names

Luis Javier

author last names

Nannini

1 reference

PubMed publication ID

19 October 2023

Toby J Lasserson

2

author given names

Toby J

author last names

Lasserson

1 reference

PubMed publication ID

19 October 2023

language of work or name

0 references

publication date

2012

0 references

Cochrane Database of Systematic Reviews

0 references

9

0 references

CD006829

0 references

Long-acting beta(2)-agonist in addition to tiotropium versus either tiotropium or long-acting beta(2)-agonist alone for chronic obstructive pulmonary disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4170910

19 March 2017

The effect of adding inhaled corticosteroids to tiotropium and long-acting beta(2)-agonists for chronic obstructive pulmonary disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4170910

19 March 2017

Combination inhaled steroid and long-acting beta(2)-agonist in addition to tiotropium versus tiotropium or combination alone for chronic obstructive pulmonary disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4170910

19 March 2017

Combined corticosteroid and long-acting beta-agonist in one inhaler versus inhaled steroids for chronic obstructive pulmonary disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4170910

19 March 2017

Combined corticosteroid and long-acting beta-agonist in one inhaler versus placebo for chronic obstructive pulmonary disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4170910

19 March 2017

Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4170910

19 March 2017

Tiotropium versus placebo for chronic obstructive pulmonary disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4170910

19 March 2017

Inhaled corticosteroids versus long-acting beta2-agonists for chronic obstructive pulmonary disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4170910

19 March 2017

Combination inhaled steroid and long-acting beta2-agonist versus tiotropium for chronic obstructive pulmonary disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4170910

19 March 2017

Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4170910

19 March 2017

Inhaled corticosteroids for stable chronic obstructive pulmonary disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4170910

19 March 2017

Long-acting beta2-agonists for poorly reversible chronic obstructive pulmonary disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4170910

19 March 2017

Combined corticosteroid and longacting beta-agonist in one inhaler for chronic obstructive pulmonary disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4170910

19 March 2017

Combined corticosteroid and longacting beta-agonist in one inhaler for chronic obstructive pulmonary disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4170910

19 March 2017

Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4170910

7 April 2017

An overview of the benefits and drawbacks of inhaled corticosteroids in chronic obstructive pulmonary disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4170910

27 September 2017

Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1-year randomized controlled clinical trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4170910

27 September 2017

Long-term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease: a meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4170910

27 September 2017

Outcomes for COPD pharmacological trials: from lung function to biomarkers.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4170910

27 September 2017

Investigating new standards for prophylaxis in reduction of exacerbations--the INSPIRE study methodology

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4170910

27 September 2017

Effect of salmeterol/fluticasone propionate on airway inflammation in COPD: a randomised controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4170910

27 September 2017

Ascertainment of cause-specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4170910

27 September 2017

Patient's perception of exacerbations of COPD--the PERCEIVE study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4170910

27 September 2017

Statistical treatment of exacerbations in therapeutic trials of chronic obstructive pulmonary disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4170910

27 September 2017

Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4170910

27 September 2017

Effect of exacerbations on quality of life in patients with chronic obstructive pulmonary disease: a 2 year follow up study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4170910

27 September 2017

Inhaled corticosteroids reduce the progression of airflow limitation in chronic obstructive pulmonary disease: a meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4170910

27 September 2017

Toward a consensus definition for COPD exacerbations

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4170910

27 September 2017

Quality of life and hospital re-admission in patients with chronic obstructive pulmonary disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4170910

27 September 2017

Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4170910

30 May 2018

Effect of fluticasone propionate/salmeterol (250/50) on COPD exacerbations and impact on patient outcomes

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006829.PUB2

21 January 2018

Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006829.PUB2

21 January 2018

Cost effectiveness of budesonide/formoterol in a single inhaler for COPD compared with each monocomponent used alone

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006829.PUB2

21 January 2018

Salmeterol & fluticasone 50 microg/250 microg bid in combination provides a better long-term control than salmeterol 50 microg bid alone and placebo in COPD patients already treated with theophylline

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006829.PUB2

21 January 2018

Effect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbations

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006829.PUB2

21 January 2018

The efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPD.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006829.PUB2

21 January 2018

Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006829.PUB2

21 January 2018

Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006829.PUB2

21 January 2018

Relationship between respiratory symptoms and medical treatment in exacerbations of COPD.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006829.PUB2

21 January 2018

Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006829.PUB2

21 January 2018

Efficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6-month randomized clinical trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006829.PUB2

21 January 2018

The TORCH (towards a revolution in COPD health) survival study protocol

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006829.PUB2

21 January 2018

Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006829.PUB2

21 January 2018

Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006829.PUB2

21 January 2018

Gender does not influence the response to the combination of salmeterol and fluticasone propionate in COPD.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006829.PUB2

21 January 2018

The effect of bronchodilators and oxygen alone and in combination on self-paced exercise performance in stable COPD.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006829.PUB2

21 January 2018

Long-acting beta2-agonists for chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006829.PUB2

21 January 2018

Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006829.PUB2

21 January 2018

Long-acting beta 2 -agonist in addition to tiotropium versus either tiotropium or long-acting beta 2 -agonist alone for chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006829.PUB2

21 January 2018

Combined corticosteroid and long-acting beta-agonist in one inhaler versus long-acting beta-agonists for chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006829.PUB2

21 January 2018

Effect of Fluticasone Propionate/Salmeterol on Lung Hyperinflation and Exercise Endurance in COPD

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006829.PUB2

21 January 2018

Inhalation combination therapy in chronic obstructive lung disease. TRISTAN-study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4170910

29 November 2018

Evaluating symptoms in chronic obstructive pulmonary disease: validation of the Breathlessness, Cough and Sputum Scale.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4170910

29 November 2018

Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4170910

29 November 2018

Efficacy of salmeterol xinafoate in the treatment of COPD

1 reference

https://pubmed.ncbi.nlm.nih.gov/22972099

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

St. George's Respiratory Questionnaire: MCID

1 reference

https://pubmed.ncbi.nlm.nih.gov/22972099

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lower inhaled steroid requirement with a fluticasone/salmeterol combination in family practice patients with asthma or COPD

1 reference

https://pubmed.ncbi.nlm.nih.gov/22972099

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Fast onset of effect of budesonide/formoterol versus salmeterol/fluticasone and salbutamol in patients with chronic obstructive pulmonary disease and reversible airway obstruction

1 reference

https://pubmed.ncbi.nlm.nih.gov/22972099

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1002/14651858.CD006829.PUB2

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

release_6smghqtx3rg6xiupehbda74a6u

0 references

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

PMC publication ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

PubMed publication ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q24200446&oldid=1993762208"